Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark R Albertini

Showing results (31-40 of 61) with videos related to

Pageof 7
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 21, 2009
Immunogenicity and antitumor effects of vaccination with peptide vaccine+/-granulocyte-monocyte colony-stimulating factor and/or IFN-alpha2b in advanced metastatic melanoma: Eastern Cooperative Oncology Group Phase II Trial E1696John M Kirkwood, Sandra Lee, Stergios J Moschos, et al.
The American Journal of Dermatopathology|July 28, 2025
Malignant Melanoma With Transdifferentiation Into a Ganglioneuroblastic Phenotype After Anti-PD-1 TherapyMadison S Harris, Claire Castaneda, Aaron Wieland, et al.
Cancer Immunology, Immunotherapy : CII|June 9, 2012
Phase II trial of hu14.18-IL2 for patients with metastatic melanomaMark R Albertini, Jacquelyn A Hank, Brian Gadbaw, et al.
Veterinary Medicine and Science|October 26, 2017
Pilot study of safety and feasibility of DNA microseeding for treatment of spontaneous canine melanomaCindy L Zuleger, Chulhi Kang, Erik A Ranheim, et al.
Cancer Immunology, Immunotherapy : CII|September 28, 2005
Phase I trial of combined treatment with ch14.18 and R24 monoclonal antibodies and interleukin-2 for patients with melanoma or sarcomaBrian S Choi, Paul M Sondel, Jacquelyn A Hank, et al.
The Journal of Investigative Dermatology|October 26, 2012
MAGE-C2 promotes growth and tumorigenicity of melanoma cells, phosphorylation of KAP1, and DNA damage repairNeehar Bhatia, Tony Z Xiao, Kimberly A Rosenthal, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 16, 2004
Phase I clinical trial of the immunocytokine EMD 273063 in melanoma patientsDavid M King, Mark R Albertini, Heidi Schalch, et al.
Cancer|June 25, 2026
Updates on intratumoral therapies in melanomaVincent T Ma, Alyssa K Steimle, Janmesh D Patel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 14, 2018
E3611-A Randomized Phase II Study of Ipilimumab at 3 or 10 mg/kg Alone or in Combination with High-Dose Interferon-α2b in Advanced MelanomaAhmad A Tarhini, Sandra J Lee, Xiaoxue Li, et al.
Melanoma Research|May 20, 2024
Administration of intratumoral GD2-directed interleukin-2 immunocytokine and local radiation therapy to activate immune rejection of spontaneous canine melanomaMark R Albertini, Cindy L Zuleger, Erik A Ranheim, et al.
Pageof 7

Showing results (31-40 of 61) with videos related to

Sort By:
Pageof 7
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 21, 2009
Immunogenicity and antitumor effects of vaccination with peptide vaccine+/-granulocyte-monocyte colony-stimulating factor and/or IFN-alpha2b in advanced metastatic melanoma: Eastern Cooperative Oncology Group Phase II Trial E1696John M Kirkwood, Sandra Lee, Stergios J Moschos, et al.
The American Journal of Dermatopathology|July 28, 2025
Malignant Melanoma With Transdifferentiation Into a Ganglioneuroblastic Phenotype After Anti-PD-1 TherapyMadison S Harris, Claire Castaneda, Aaron Wieland, et al.
Cancer Immunology, Immunotherapy : CII|June 9, 2012
Phase II trial of hu14.18-IL2 for patients with metastatic melanomaMark R Albertini, Jacquelyn A Hank, Brian Gadbaw, et al.
Veterinary Medicine and Science|October 26, 2017
Pilot study of safety and feasibility of DNA microseeding for treatment of spontaneous canine melanomaCindy L Zuleger, Chulhi Kang, Erik A Ranheim, et al.
Cancer Immunology, Immunotherapy : CII|September 28, 2005
Phase I trial of combined treatment with ch14.18 and R24 monoclonal antibodies and interleukin-2 for patients with melanoma or sarcomaBrian S Choi, Paul M Sondel, Jacquelyn A Hank, et al.
The Journal of Investigative Dermatology|October 26, 2012
MAGE-C2 promotes growth and tumorigenicity of melanoma cells, phosphorylation of KAP1, and DNA damage repairNeehar Bhatia, Tony Z Xiao, Kimberly A Rosenthal, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 16, 2004
Phase I clinical trial of the immunocytokine EMD 273063 in melanoma patientsDavid M King, Mark R Albertini, Heidi Schalch, et al.
Cancer|June 25, 2026
Updates on intratumoral therapies in melanomaVincent T Ma, Alyssa K Steimle, Janmesh D Patel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 14, 2018
E3611-A Randomized Phase II Study of Ipilimumab at 3 or 10 mg/kg Alone or in Combination with High-Dose Interferon-α2b in Advanced MelanomaAhmad A Tarhini, Sandra J Lee, Xiaoxue Li, et al.
Melanoma Research|May 20, 2024
Administration of intratumoral GD2-directed interleukin-2 immunocytokine and local radiation therapy to activate immune rejection of spontaneous canine melanomaMark R Albertini, Cindy L Zuleger, Erik A Ranheim, et al.
Pageof 7